US Peptide Science Research Team
August 31, 2026
Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist under development by Eli Lilly for chronic weight management and metabolic disease. As of 2026, retatrutide remains an investigational drug in Phase 3 clinical trials and has not been approved by the FDA for any indication. qz.com Lilly announced in July 2026 that it would file a New Drug Application with the FDA in the first quarter of 2027, with potential approval estimated for late 2027 or 2028. Because retatrutide is unapproved, it cannot be legally prescribed, dispensed by pharmacy, or sold as a finished medicine in the United States outside of clinical trials or the expanded access pathway.
Expanded access, sometimes called compassionate use, is an FDA regulatory pathway that permits use of an investigational drug outside a clinical trial when a patient has a serious or immediately life-threatening condition, lacks a comparable satisfactory approved treatment, cannot enroll in a trial, and faces risks justified by potential benefit. nchstats.com Critically, expanded access authorization does not mean the FDA has found retatrutide safe and effective. Rather, the agency permits a specific treatment request under investigational-drug safeguards.
Lilly formalized an expanded access program for retatrutide in August 2026, after months of physician requests. qz.com The FDA prefers that patients receive experimental products in clinical trials, where eligibility, dosing, monitoring, and data collection follow a defined protocol.
Access is deliberately narrow and cumulative. According to Eli Lilly and FDA guidance, patients must meet all of the following criteria:
Meeting every criterion does not guarantee approval. Lilly states that availability will depend on geography, product supply, and detailed individual eligibility assessment. nchstats.com
Patients do not apply directly to Lilly or the FDA. The process is physician-initiated:
This pathway was designed for refractory severe obesity with serious complications—not as a shortcut for early access.
Phase 3 trials conducted by Eli Lilly reported efficacy data alongside dose-related tolerability findings. In the highest-dose group (12 milligrams), participants demonstrated substantial weight loss. qz.com Specifically, participants on the 12 mg dose lost an average of 28.3% of their body weight over 80 weeks. qz.com For patients with a BMI over 35, weight loss was reported at approximately 30.3% of body weight after two years. fox2detroit.com
Gastrointestinal adverse events were commonly reported in Phase 3 trials. At the 12-milligram dose, the following were observed:
fox2detroit.com Adverse events caused 11% of participants at the 12-milligram dose to discontinue treatment. qz.com Detailed peer-reviewed publication of Phase 3 data remains important for evaluating subgroup effects, uncommon harms, and how findings hold up under independent scrutiny. As of 2026, Phase 3 results have been released as topline data but full peer-reviewed publication is pending.
The FDA has explicitly warned against compounding of retatrutide. nchstats.com Products advertised online as retatrutide are not FDA-approved versions of Lilly's medicine. nchstats.com The agency has warned sellers against marketing unapproved retatrutide and other experimental peptides. nchstats.com
Online vendors sell products labeled as retatrutide for "research purposes" or "not for human consumption." The research-use-only disclaimer is the entire legal shield: by labeling the product as research-use-only, sellers attempt to avoid the regulations that apply to medicines. However, this route carries significant risks:
The expanded access program creates a legal route to Lilly-manufactured, pharmaceutical-grade retatrutide for qualifying patients. It does not legalize pharmacy-made copies, online peptide vials, med-spa sales, or regular prescriptions written outside the program. nchstats.com
As of 2026, there are two legal pathways:
Clinical trials: Lilly is conducting multiple Phase 3 trials at numerous U.S. sites. qz.com Clinical trial participation involves full medical supervision and FDA-regulated, GMP-manufactured product.
Expanded access (compassionate use): Available through Lilly's program for severely affected patients who meet all eligibility criteria and cannot access a trial. nchstats.com The FDA notes that costs may not be covered by insurance. nchstats.com
Both routes involve pharmaceutical-grade product, full medical supervision, and FDA oversight. Neither is a shortcut; both require physician involvement and regulatory review.
Lilly announced in July 2026 that it would file a New Drug Application with the FDA in Q1 2027. qz.com If approved on the typical timeline, retatrutide could become available as a prescribed medication in late 2027 or 2028. Until then, retatrutide remains investigational and unapproved. The expanded access program represents a bridge for a small number of patients with severe, refractory disease and serious complications—not a general early-access route.
When researching retatrutide or related GLP-1/GIP/glucagon receptor agonists, it is essential to distinguish between:
The expanded access program reflects a regulatory shift from gray-market chaos to FDA-guided, physician-supervised access for a narrow, high-need population. It is neither an approval nor a shortcut—it is a compassionate-use pathway with rigorous gatekeeping.